Targeting Vascular Endothelial Growth Factor Receptors as a Therapeutic Strategy for Osteoarthritis and Associated...

Area of Science:

• Biomedical Science
• Pain Research
• Osteoarthritis Pathophysiology

Background:

• Osteoarthritis (OA) is a leading cause of chronic pain, significantly impacting patient quality of life.
• Vascular Endothelial Growth Factors (VEGFs) and their receptors (VEGFRs) are implicated in OA pain signaling pathways.
• Understanding the specific roles of VEGF/VEGFR signaling in OA progression and pain is crucial for developing effective treatments.

Purpose of the Study:

• To elucidate the distinct contributions of VEGF ligands and their receptors (VEGFR1 and VEGFR2) in mediating OA pain and joint pathology.
• To evaluate the therapeutic potential of VEGFR inhibitors in a preclinical OA model.

Main Methods:

• Intra-articular (IA) injections of VEGF ligands were administered to murine knee joints to assess pain induction.
• A preclinical murine OA model was treated with IA injections of selective VEGFR1/VEGFR2 kinase inhibitor (pazopanib) or VEGFR2 kinase inhibitor (vandetanib).
• OA phenotypes were evaluated using behavioral pain tests and histopathology; VEGF/VEGFR signaling alterations were analyzed via immunofluorescence microscopy.

Main Results:

• VEGF ligands activating VEGFR1, but not VEGFR2, induced rapid allodynia in OA models.
• Pazopanib treatment resulted in immediate OA pain relief by interfering with pain transmission pathways.
• Vandetanib primarily reduced cartilage degeneration by inhibiting VEGFR2 expression, with less immediate pain relief compared to pazopanib.

Conclusions:

• Intra-articular pazopanib, a dual VEGFR1/VEGFR2 inhibitor, demonstrates potential as a disease-modifying osteoarthritis drug.
• Pazopanib offers rapid OA pain reduction and simultaneous inhibition of cartilage degeneration.
• Targeting VEGF/VEGFR signaling presents a promising therapeutic strategy for managing OA pain and pathology.